StreetAlpha.app
Home › Stocks › PTGX

Protagonist Therapeutics, Inc (PTGX)

Healthcare
$124.67
▼ −0.13%
LAST CLOSE · NOV 17

Protagonist Therapeutics develops peptide and small molecule medicines for inflammatory, blood and metabolic diseases. It last closed at $124.67 on Nov 17, down 0.13% on the day. The average 12-month price target from 7 analysts is $186.71 (+49.8% from the last close), with a high of $221.00 and a low of $160.00. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (7 buy, 0 hold, 0 sell).

AI Auto Pilots
Is PTGX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$551.7M
+163.7% vs a year ago
Net income
$342.3M
+645.5% vs a year ago
EPS (diluted)
$4.73
+616.7% vs a year ago
Free cash flow
$109.1M
19.8% margin
Valuation
Market cap
$8.1B
65.3M shares
P/E
26.4
Price over 12 month EPS
Price to sales
14.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$498.3M
At Sep 30
Shareholder equity
$1.1B
Shares outstanding
65.3M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $27.4M$27.4MFY2021FY2022: $26.6M$26.6MFY2022FY2023: $60.0M$60.0MFY2023FY2024: $434.4M$434.4MFY2024FY2025: $46.0M$46.0MFY2025

From PTGX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 7 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
7firms
7 Buy0 Hold0 Sell
Each firm's latest rating on PTGX in the past 90 days
Average 12-month target
$186.71
▲ 49.8% upside

Based on 7 analysts who set a price target on PTGX in the past 90 days. The average target is $186.71, with a high of $221.00 and a low of $160.00, compared with the last close of $124.67.

Low $160.00Avg $186.71High $221.00
Blue marker: last close $124.67
Highest target$221.00
Average target$186.71
Lowest target$160.00
Latest rating changes
HC Wainwright & Co.Target raised
Nov 6Buy$170 → $221
TD CowenMaintained
Oct 21Buy$160
UBSInitiated
Oct 12Buy$184
Leerink PartnersAssumed coverage
Oct 12Buy$190
BarclaysTarget raised
Sep 1Buy$153 → $180
DateFirmActionRatingPrice target
Nov 6HC Wainwright & Co.Target raisedBuy$170 → $221
Oct 21TD CowenMaintainedBuy$160
Oct 12UBSInitiatedBuy$184
Oct 12Leerink PartnersAssumed coverageBuy$190
Sep 1BarclaysTarget raisedBuy$153 → $180
Loading…

Technical Analysis

PTGX · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, nearing oversold

The stock is 10% below its 20 day and 12% below its 50 day average. It is 4% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 32), near oversold. The nearest support is the Pivot at $124.11, and the nearest resistance the Pivot R1 at $126.46.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 4.6%/day
Key levels
$160.8152 week high+29.0%
$140.47100 day average+12.7%
$139.4650 day average+11.9%
$138.82Swing high (Nov 12)+11.3%
$137.0520 day average+9.9%
$126.46Pivot R1+1.4%
$124.67Last close
$124.11Pivot−0.4%
$122.31Pivot S1−1.9%
$119.71200 day average−4.0%
$118.27Swing low (Jun 29)−5.1%
$77.0052 week low−38.2%
Indicators
RSI (14)32.47Weak, oversold below 30Neutral
MACD-3.18Below its signal lineBearish
Stochastic10.5Near the bottom of its rangeOversold
ADX (14)23.5Weak trend
Williams %R-88.2Oversold below −80, overbought above −20Oversold
CCI (20)-207.6Oversold below −100, overbought above 100Oversold
Rate of change−11.1%Change over 10 sessionsBearish
ATR (14)$5.79Typical daily range, 4.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for PTGX

What happened before

See how PTGX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PTGX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PTGX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PTGX in the last 90 days.

Loading…

See today’s whale options flow across the market →

PTGX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲228 buying vs 138 selling
  • ▲Held by funds +2.2 pts
  • ▲Funds holding +36
  • ▼Superinvestors: 1 added, 2 cut
  • ▲Put/call 0.53 to 0.50
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding383347+10.4%
In funds' top 10910−10.0%
Held by funds118.5%116.3%+2.2 pts
New / increased81 / 14761 / 138+14.6%
Reduced / sold out94 / 4487 / 37+11.3%
Put/call ratio0.500.53−5.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PTGX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PTGX is in one of them and how their past PTGX trades turned out.

PTGX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PTGX in an article yet. Here's the latest on the wider market.

PTGX Congress Trades

All congress trades →
Trades, 12 months
2
Buys
0
0%
Sells
2
100%
People
1
Last filed Sep 22
Who traded PTGX · since 2026
Latest 2 filings
$15K – $50KTraded Jul 29, 2026Filed Sep 22, 2026
$15K – $50KTraded May 15, 2026Filed Jul 1, 2026
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchSell$15K – $50KJul 29, 2026Sep 22, 202655 d
Donald J TrumpExecutive branchSell$15K – $50KMay 15, 2026Jul 1, 202647 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Protagonist Therapeutics

Protagonist Therapeutics is a drug discovery and development company based in Newark, California. It is developing medicines for inflammatory skin conditions, a rare blood disorder called polycythemia vera, and obesity. Its key candidates include Icotyde, a treatment for plaque psoriasis being developed with Johnson & Johnson, and rusfertide, an injectable therapy for polycythemia vera developed with Takeda. These medicines are intended for patients with these conditions, and its partners are large drugmakers.

Headquarters
Newark, CA